Literature DB >> 33239860

Assessment of Diabetic Retinopathy Vascular Density Maps.

Passant Sayed Saif1, Abd El-Rahman Gaber Salman2, Norhan Amr Hassan Omran1, Yousra Ahmed Thabet Farweez2.   

Abstract

PURPOSE: Optical coherence tomography (OCT) and OCTA were used for qualitative and quantitative assessment of retinal vascular density in superficial capillary plexus, deep capillary plexus, foveal avascular zone, and choroidal vascular density map. PATIENTS AND METHODS: This study included 64 eyes. Diabetics and control groups were recruited from an internal medicine clinic at Misr University for Science and Technology Hospital and asked to participate in this study. This study was designed as an observational and cross-sectional study in the period from 8/2018 to 8/2019.
RESULTS: There was a decrease in choroidal vascular density in diabetic patients. There was a decrease in retinal thickness in diabetic patients and there were no significant differences in the retinal thickness between control subjects and patients with non-diabetic retinopathy (NDR).
CONCLUSION: Our study suggests that OCTA can identify preclinical DR before the manifestation of clinically apparent retinopathy. Our findings also highlight the potential role of OCTA in monitoring and quantifying retinal vascular alterations in diabetics.
© 2020 Saif et al.

Entities:  

Keywords:  diabetic retinopathy; optical coherence tomography angiography

Year:  2020        PMID: 33239860      PMCID: PMC7680795          DOI: 10.2147/OPTH.S256963

Source DB:  PubMed          Journal:  Clin Ophthalmol        ISSN: 1177-5467


Introduction

Diabetic retinopathy (DR) is one of the leading causes of vision loss, either due to macular edema or vitreous hemorrhage.1 The greater the duration of diabetes the greater the chance of developing DR.2 Microvascular changes including capillary remodeling, regression, and decreased density have been proven through histopathological and imaging studies to be the cause of DR changes.3 The non-invasive dye-free Optical Coherence Tomography Angiography (OCTA) facilitates the visualization of both choroidal and retinal vasculature, thus allowing the detection of angiographic features of DR. OCTA can detect areas of non-perfusion in both superficial and deep plexuses; also microaneurysms have been outlined clearly.4 OCTA delineates pathogenic changes in the foveal microvascular networks and quantify superficial retinal capillary plexus precisely.5 OCTA has been used in recent studies in macular vessel density quantification.6 The longer wavelength Swept-source-OCT (SS-OCTA) allows for deeper and more clear penetration up to sclero-choroidal interface. It also has a fast scanning speed7 that was used in qualitative and quantitative assessment of retinal and choroidal vascular density in diabetic patients in this study.

Patients and Methods

This study included 64 eyes. Diabetics and control groups were recruited from an internal medicine clinic at Misr University for Science and Technology Hospital and asked to participate in this study. This study was designed as an observational and cross-sectional study during the period from 8/2018 to 8/2019. The study was approved by the Faculty of Medicine Ain Shams University IRB and the ophthalmology department council Ain Shams University and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Inclusion criteria: Both sexes, male and female, ages 30–60 years old. Best-corrected visual acuity (BCVA) greater than 0.5 LogMAR in the study eye at baseline examination to ensure proper execution of examination. Diabetic Patients are defined according to World Health Organization guidelines as fasting plasma glucose ≥ 126 mg/dl or 2-h plasma glucose ≥ 200 mg/dl or being on antidiabetic medication. The controls (group N) had normal glycaemic values.8 Exclusion criteria: IOP more than 21 mmHg. High Myopia. Media opacity in the study eye. Scans with poor image quality met these criteria: (1) poor fixation resulting in a double vessel pattern and motion artifacts, (2) weak local signal or poor clarity, (3) macular edema, and (4) macular segmentation errors.10,11 Study Population: Eyes were divided into four groups. Group 1 consisted of 16 eyes of normal healthy individuals (control group); Group 2 consisted of 16 eyes with a clinical diagnosis of non-diabetic retinopathy; Group 3 consisted of 16 eyes with the clinical diagnosis of non-proliferative diabetic retinopathy; and Group 4 consisted of 16 eyes with the clinical diagnosis of proliferative diabetic retinopathy. Study design: All subjects participating in the study were asked to sign a consent before inclusion. They were then subjected to full medical and family histories. Careful ocular examination was performed on the day of OCT assessment. The ocular examination included: a. Uncorrected visual acuity (UCVA) and BCVA using a Snellen chart and converted to LogMAR: the patient was 6 m away from the chart; one eye at a time was tested with the fellow eye occluded. b. Intraocular pressure by Goldman applanation tonometer. c. Anterior and posterior segment examination by a slit-lamp biomicroscopy. d. Dilated fundus examination with both slit-lamp biomicroscopy with a 90D lens and indirect ophthalmoscopy. Prepare the patient: Confirm adequate dilation. Inform patients of procedures, pharmacological agents to be administered, and potential side effects. Position patient for photography. OCT: Swept-source (SS)-OCT and OCTA image acquisition. During the same visit, all study subjects underwent SS-OCT examination (DRI Triton, Topcon, Tokyo, Japan), which contains a 1050-nm-wavelength swept light source and has a scanning speed of 100,000 A-scans/second.9 OCT was done to acquire: a. Retinal thickness at the fovea and parafoveal area using a six-line radial pattern scan (1024 A-scans) centered on the fovea from each eye. b. Choroidal thickness measured (nasal, temporal, superior and inferior) at 2 mm from the fovea. We obtained a six-line radial pattern scan (1024 A-scans) centered on the fovea from each eye. The definition of choroidal thickness is the vertical distance between the posterior edge of the hyper-reflective retinal pigment epithelium and the choroid/sclera junction. The choroidal thickness was manually measured using a built-in caliper in the OCT software. OCTA was done to study quantitatively and qualitatively: Using quantitative measuring of the Foveal Avascular Zone (FAZ) area at the superficial capillary plexus (SCP), using the 3x3 mm scan, the FAZ area and perimeter were outlined manually along the innermost capillaries on OCTA images at the SCP. SCP and deep capillary plexus (DCP) (qualitative analysis) at the parafoveal area in the 4.5x4.5 mm scan. Quantitative measuring of the retinal vessel density map at the SCP in the 4.5x4.5 mm scan was measured automatically by the device. Measuring the choroidal vessel density map in the 4.5x4.5 mm scan was measured manually by the operator by applying a superior line at the level of Bruch’s membrane and an inferior line at the sclera-choroidal interface (SCI). The OCT device automatically segments the layers using a built-in segmentation algorithm for the superficial plexus 2.6 μm below the internal limiting membrane to 15.6 μm below the junction between the inner plexiform and inner nuclear layers (IPL/INL) and deep plexus 15.6 μm below the IPL/INL to 70.2 μm below the IPL/INL. Enface projections of volumetric scans allow for the visualization of structural and vascular details within segmented retinal layer boundaries. Only OCT images with a signal strength index >60 were used and scans with poor image quality were excluded.

Statistical Analysis

Data Management and Analysis: The collected data were revised, coded, tabulated and introduced to a PC using a statistical package for social sciences (IBM SPSS 20.0). Data were presented and suitable analysis was done according to the type of data obtained for each parameter. I. Descriptive Statistics: 1. Mean, Standard deviation (+ SD) and range for parametric numerical data, while Median and Interquartile range (IQR) for non-parametric data. 2. Frequency and percentage of non-numerical data. II. Analytical Statistics: 1. ANOVA was used to assess the statistical significance of the difference of a parametric variable between means of more than two study groups. Post hoc test was performed to assess statistical significance within groups 2. Chi-square test was used to examine the relationship between two qualitative variables but when the expected count was less than 5 in more than 20% of the cells, Fisher’s exact test was used. P-value: Level of significance: P>0.05: Non-significant (NS). P<0.05: Significant (S). P<0.01: Highly significant (HS)

Results

This study included four groups. Group 1 was the control group of normal individuals; Group 2 was diabetic patients with no evidence of diabetic retinopathy changes; Group 3 was diabetic patients with non-proliferative diabetic retinopathy; and Group 4 was diabetic patients with proliferative diabetic retinopathy. There were 45.3% female versus 54.7% male, ranging in age between 35 and 51 years, included in this study. The mean values Age in control group was 38.31 ± 8.93 SD, while the mean values were higher in the No Diabetic Retinopathy group, the Non-Proliferative DR group, and the Proliferative DR group (42.19±14.01, 49.3±8.5 and 50.75±7.37) respectively. These differences were statistically highly significant as shown in Table 1
Table 1

Demographic Data and Examination Analysis of Patients

VariablesDiagnosisANOVAP-value
ControlNon-Diabetic RetinopathyNon-Proliferative DRProliferative DR
Mean± SDMean± SDMean± SDMean± SD
Vision LOG MAR0.010.030.030.060.040.070.180.1611.0730.000**
IOP12.001.4612.191.1112.691.6213.061.341.9130.137
Age38.318.9342.1914.0149.388.5950.757.375.5300.002**
Post hoc analysis
P1P2P3P4P5P6
Vision LOG MAR0.5690.3440.000**0.5690.7040.000**
Age0.2800.001**0.003**0.0580.025*0.692

Notes: *Statistically significant at P<0.05. P1: Comparison between control vs non-diabetic retinopathy. P2: Control vs non-proliferative DR. P3: Control vs proliferative DR. P4: no diabetic retinopathy vs non-proliferative DR. P5: no diabetic retinopathy vs proliferative DR. P6: Non-proliferative DR vs proliferative DR.

Demographic Data and Examination Analysis of Patients Notes: *Statistically significant at P<0.05. P1: Comparison between control vs non-diabetic retinopathy. P2: Control vs non-proliferative DR. P3: Control vs proliferative DR. P4: no diabetic retinopathy vs non-proliferative DR. P5: no diabetic retinopathy vs proliferative DR. P6: Non-proliferative DR vs proliferative DR. OCT showed no significant changes in retinal parafoveal thickness but a highly significant decrease in retinal foveal thickness (Figure 1). There was a highly significant decrease in choroidal thickness (Figure 2) as well in superior, inferior and nasal quadrants, and to a lesser extent, a significant decrease in temporal choroidal thickness as shown in Table 2.
Figure 1

Sample of retinal thickness in different study groups.

Figure 2

Sample of choroidal thickness in different study groups.

Table 2

Comparison of Foveal Thickness Between Study Groups

VariablesDiagnosisANOVAP-value
ControlNon-Diabetic RetinopathyNon-Proliferative DRProliferative DR
Mean± SDMean± SDMean± SDMean± SD
Foveal Thickness (µm)238.502.97238.061.61233.750.77230.251.4868.6400.000**
Sup Parafoveal (µm)310.699.39309.3811.22308.8816.24299.4415.282.3970.077
Inf Parafoveal (µm)296.3811.86294.1336.39292.0631.38291.7525.110.0960.962
Nasal Parafoveal (µm)300.8124.02300.509.61296.6328.35282.6232.951.8330.151
Temporal Parafoveal (µm)293.5612.27292.4416.63292.1913.18290.5012.090.1370.938
Superior Choroidal thickness (µm)265.5014.65229.502.10225.311.70196.5621.6574.0630.000
Inferior Choroidal thickness (µm)266.8140.45236.3126.56234.252.91173.8813.9238.1020.000
Nasal Choroidal thickness255.0023.74226.313.34218.883.34186.5631.2132.4470.000
Tempo Choroidal thickness (µm)251.0650.10234.1335.92231.8873.54191.3170.432.9010.042
Post hoc analysis
P1P2P3P4P5P6
Foveal thickness (μm)0.5140.000**0.000**0.000**0.000**0.000**
Sup choroidal thickness0.000**0.000**0.000**0.3710.000**0.000**
Inf choroidal thickness0.001**0.001**0.000**0.8180.000**0.000**
Nasal choroidal thickness0.000**0.000**0.000**0.2910.000**0.000**
Temporal choroidal thickness0.4240.3660.006**0.9150.046*0.059

Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Comparison between control vs non-diabetic retinopathy. P2: Control vs non-proliferative DR. P3: Control vs proliferative DR. P4: no diabetic retinopathy vs non-proliferative DR. P5: no diabetic retinopathy vs proliferative DR. P6: Non-proliferative DR vs proliferative DR.

Comparison of Foveal Thickness Between Study Groups Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Comparison between control vs non-diabetic retinopathy. P2: Control vs non-proliferative DR. P3: Control vs proliferative DR. P4: no diabetic retinopathy vs non-proliferative DR. P5: no diabetic retinopathy vs proliferative DR. P6: Non-proliferative DR vs proliferative DR. Sample of retinal thickness in different study groups. Sample of choroidal thickness in different study groups. On measuring the FAZ area, both the proliferative and the non-proliferative DR groups showed a highly significant increase in its size while the non-diabetic retinopathy evident group showed no significant change in area size as compared to the control group as shown in Table 3 and Figure 3.
Table 3

Comparison of FAZ Area, Retinal and Choroidal Vascular Density in Studied Groups

VariablesDiagnosisANOVAP-value
Control (2)Non-Diabetic Retinopathy (3)Non-Proliferative DR (1)Proliferative DR (4)
Mean± SDMean± SDMean± SDMean± SD
FAZ area (mm)0.290.020.290.040.400.050.480.0657.9150.000**
Sup retinal density55.740.5753.361.8352.101.3142.574.3488.1780.000**
Inf retinal density56.871.8954.191.2450.711.9743.283.7795.5210.000**
Nasal density48.431.2946.031.1145.011.3641.551.2582.8610.000**
Temporal density53.682.0552.921.3650.291.2040.772.87143.4740.000**
Choroidal density sup50.680.6848.232.3244.192.3440.285.6031.4120.000**
Choroidal inf.53.774.1649.180.9346.580.8038.354.2073.5760.000**
Choroidal nasal49.464.5745.732.4145.042.0442.311.0817.3340.000**
Choroidal density57.435.8847.351.7944.462.9140.673.1358.8630.000**

Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01.

Figure 3

Sample of FAZ area in different study groups.

Comparison of FAZ Area, Retinal and Choroidal Vascular Density in Studied Groups Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. Sample of FAZ area in different study groups. Both the superficial (Figure 4) and choroidal (Figures 5 and 6) vessel density maps showed a highly significant decrease in vessel density in all groups compared to the control group as shown in Table 3 (Figure 7).
Figure 4

Vessel density map in the Superficial Capillary plexus of different groups.

Figure 5

Choroidal density map in the Superficial Capillary plexus of different groups.

Figure 6

Deep Capillary plexus vessel density map.

Figure 7

Graph comparing the 4 groups as regards the vascular density and choroidal density.

Vessel density map in the Superficial Capillary plexus of different groups. Choroidal density map in the Superficial Capillary plexus of different groups. Deep Capillary plexus vessel density map. Graph comparing the 4 groups as regards the vascular density and choroidal density. On comparing the control group to the no evidence of DR group (P1), the superficial vessel density maps showed a highly significant decrease in vessel density in superior, inferior and nasal vessel density maps but no statistically significant decrease in the temporal quadrant. However, there was a highly statistically significant decrease in all quadrants when the control group was compared to the non-proliferative and proliferative groups (P2 and P3) respectively, as shown in Table 4.
Table 4

Post Hoc Test Displaying Multiple Comparisons Within Groups Regarding the FAZ Area, Superior Retinal Density, Inferior Retinal Density, Nasal Density and Temporal Density

Post Hoc Analysis
P1P2P3P4P5P6
FAZ area0.6810.000**0.000**0.000**0.000**0.000**
Sup retinal density0.008**0.000**0.000**0.1530.000**0.153
Inf retinal density0.003**0.000**0.000**0.000**0.000**0.000**
Nasal density0.000**0.000**0.000**0.025*0.000**0.000**
Temporal density0.2810.000**0.000**0.000**0.000**0.000**

Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Control group versus non-DR group. P2: Control group versus non-proliferative DR group. P3: Control group versus proliferative DR group. P4: Non-DR group versus non-proliferative DR group. P5: Non-DR group versus proliferative DR group. P6: Non-proliferative DR group versus proliferative DR group.

Post Hoc Test Displaying Multiple Comparisons Within Groups Regarding the FAZ Area, Superior Retinal Density, Inferior Retinal Density, Nasal Density and Temporal Density Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Control group versus non-DR group. P2: Control group versus non-proliferative DR group. P3: Control group versus proliferative DR group. P4: Non-DR group versus non-proliferative DR group. P5: Non-DR group versus proliferative DR group. P6: Non-proliferative DR group versus proliferative DR group. There was a highly significant decrease in superficial vessel density in the inferior and temporal quadrants when comparing the non-DR group to the non-proliferative DR group. This comparison also showed a significant decrease in the nasal quadrant but no significant decrease in the superior quadrant (P4). Table 4 also demonstrated the highly significant decrease in the superficial vessel density map comparing the non-DR group to the proliferative DR group in all quadrants. However, comparing the non-proliferative DR group to the proliferative DR group (P6), there was no statistically significant decrease in superficial vessel density in the superior quadrant only but a highly significant decrease in the rest of the quadrants. On comparing the control group to the no evidence of DR group (P1), the choroidal vessel density maps showed a high statistically significant decrease in choroidal vessel density in the inferior, nasal, and temporal vessel density map and an only statistically significant decrease in the superior quadrant. However, there was a highly statistically significant decrease in all quadrants when the control group was compared to the non-proliferative and proliferative groups (P2 and P3) respectively, as shown in Table 5.
Table 5

Post Hoc Test Displaying Multiple Comparisons Within Groups Regarding Choroidal Density Sup., Choroidal Inf., Choroidal Nasal and Choroidal Density

Post Hoc Analysis
P1P2P3P4P5P6
Choroidal density sup.0.038*0.000**0.000**0.001**0.000**0.001**
Choroidal inf.0.000**0.000**0.000**0.018*0.000**0.000**
Choroidal nasal0.000**0.000**0.000**0.4940.001**0.008**
Choroidal density0.000**0.000**0.000**0.033*0.000**0.006**

Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Control group versus non-DR group. P2: Control group versus non-proliferative DR group. P3: Control group versus proliferative DR group. P4: Non-DR group versus non-proliferative DR group. P5: Non-DR group versus proliferative DR group. P6: Non-proliferative DR group versus proliferative DR group.

Post Hoc Test Displaying Multiple Comparisons Within Groups Regarding Choroidal Density Sup., Choroidal Inf., Choroidal Nasal and Choroidal Density Notes: *Statistically significant at P<0.05. **Highly statistically significant at P<0.01. P1: Control group versus non-DR group. P2: Control group versus non-proliferative DR group. P3: Control group versus proliferative DR group. P4: Non-DR group versus non-proliferative DR group. P5: Non-DR group versus proliferative DR group. P6: Non-proliferative DR group versus proliferative DR group. There was a statistically significant decrease in superficial vessel density in the inferior and temporal quadrants on comparing the non-DR group to the non-proliferative DR group. This comparison also showed no statistically significant decrease in the nasal quadrant but a highly significant decrease in the superior quadrant (P4). Table 5 also demonstrates the high significance decrease in the choroidal vessel density map comparing the non-DR group to the proliferative DR group in all quadrants (P5), as well as on comparing the non-proliferative DR group to the proliferative DR group (P6). Fisher’s exact test was used as a part of qualitative assessment of the capillary drop out, which was present even in Group 1 which has no evident DR changes in 5 patients amounting to 31.3%, increased to 37.5% in the non-proliferative group and highest 43.8% in the proliferative group as shown in Table 6.
Table 6

Qualitative Assessment of Capillary Drop Out in Studied Groups

Qualitative AssessmentDiagnosis
ControlNon-Diabetic RetinopathyNon-Proliferative DRProliferative DR
No.%No.%No.%No.%
Capillary drop out00.0%531.3%637.5%743.8%

Note: Fisher’s exact test was used as 20.0% of the cells or more have expected count less than 5.

Qualitative Assessment of Capillary Drop Out in Studied Groups Note: Fisher’s exact test was used as 20.0% of the cells or more have expected count less than 5. There was no statistically significant correlation between choroidal thickness and choroidal vessel density as shown in Table 7
Table 7

Correlation Between Choroidal Thickness (Superior, Inferior, Nasal and Temporal) and Choroidal Density (Superior, Inferior, Nasal and Temporal)

Superior Choroidal ThicknessInferior Choroidal ThicknessNasal Choroidal ThicknessTempochoroidal Thickness
rP-valuerP-valueRP-valuerP-value
Choroidal density sup0.2070.1570.0170.909−0.1440.328−0.0340.818
Choroidal inf−0.1450.325−0.0020.9910.0310.8320.1640.264
Choroidal nasal−0.1130.4430.160.2760.1180.4230.2430.096
Choroidal density temporal−0.2360.106−0.0550.71−0.0040.9780.1930.189
Correlation Between Choroidal Thickness (Superior, Inferior, Nasal and Temporal) and Choroidal Density (Superior, Inferior, Nasal and Temporal) There was no statistically significant correlation between retinal thickness and superficial retinal vessel density as shown in Table 8.
Table 8

Correlation Between Retinal Thickness (Superior Parafoveal, in Parafoveal Inferior, Nasal Parafoveal and Temporal Parafoveal) and Retinal Density (Superior, Inferior, Nasal and Temporal)

Sup Para FovealInf Para FovealNasal Para FovealTemporal Para Foveal
rP-valuerP-valuerP-valuerP-value
Sup retinal density−0.1010.4940.0450.759−0.1450.325−0.1710.245
Inferior retinal density0.0930.5310.0950.519−0.230.116−0.1110.452
Nasal density−0.030.8420.2310.114−0.2370.1040.0030.986
Temporal density−0.0570.7020.2260.122−0.1630.269−0.0740.616
Correlation Between Retinal Thickness (Superior Parafoveal, in Parafoveal Inferior, Nasal Parafoveal and Temporal Parafoveal) and Retinal Density (Superior, Inferior, Nasal and Temporal)

Discussion

DR is a progressive microvascular disease. OCTA can advance our understanding of DR by providing high-resolution images of retinal and choroidal microvasculature blood flow and structure.4 Previous studies4,6 have shown that many factors may affect the retina and choroid such as diabetes mellitus (DM), especially in proliferative stage of diabetic retinopathy. There is a metabolic and vascular factor or yet unknown factor that affects the thickness and morphology of the retina and choroid.4,6 Diabetes is a metabolic disease affecting the systemic vasculature. Although the principal changes in diabetic eyes occur in the retinal vasculature, additional changes are also observed in the choroidal layer, an important vascular tissue that supplies blood to the outer retina.12 Histologic studies of diabetic eyes show increased tortuosity, focal vascular dilation or narrowing and the formation of sinus-like structures between the choroidal lobules and also, in some advanced cases, luminal narrowing of the capillaries, capillary dropout, and focal scarring.13 Besides, studies using indocyanine green angiography show filling delay or defects in the choriocapillaris, saccular dilatations, microaneurysms in the choriocapillaris and choroidal neovascularization.14 Information regarding CT was based primarily on histologic examinations which do not necessarily reflect the measurements of this dynamic tissue in vivo.15 In our study, there is a decrease in choroidal thickness in the diabetic patient. In agreement with our study, Querques et al16 identified choroidal thinning despite the disease stage, even in diabetic patients without DR, Sudhalkar et al17 described a progressive thinning of CT with increasing severity of DR, Regatieri et al18 states that it is unclear whether the choroidal thinning is primary or secondary to retinal ischemia. This study suggests that choroidal thinning precedes the onset of retinal pathology and the thinning increases with progressive worsening of the retinopathy. In contrast to our study Kim et al19 reports an increased CT in patients with increasing severity of DR, and while the exact mechanism they state is unknown, there is conflicting evidence on the change in retinal blood flow and pulsatile ocular blood flow in subjects with diabetes.20 In our study, there is an increase in the FAZ area in diabetic patients. In agreement with de Carlo et al21 who have reported increase FAZ in NDR, Hwang et al6 reported statistically significant enlargement in patients with DR. In contrast to our study, Scarinci et al22 did not find differences between T1DM patients with NDR and normal controls in the FAZ area of both superficial and deep capillary plexus. In our study, there is a decrease in vessel density at the superficial capillary plexus. In agreement with our study Kim et al23 have detected progressively decreasing capillary density, branching complexity, and progressively increasing average vascular caliber in eyes with different stages of DR. They have not been able to detect a significant difference in these variables between healthy subjects and patients with mild non-proliferative DR. Significantly reduced density in the superficial vascular plexus in mild non-proliferative DR in comparison to control subjects has also been observed in the study of Agemy et al.24 Also, Dimitrova et al25 had a reduction in parafoveal superficial and deep retinal vessel density in diabetic eyes compared to healthy subjects. In our study, there is a decrease in choroidal vascular density. In agreement with our study, Nagaoka et al20 demonstrated that there was a decreased choroidal blood flow, even before visible DR was present.24 Also, previous studies report that choroidal circulation, estimated by color Doppler imaging of posterior ciliary arteries, is significantly decreased in patients with background DR.26 Nagaoka et al20 suggest that choroidal hypoperfusion might trigger the development of DR due to retinal tissue hypoxia and overexpression of VEGF. Schocket et al27 report that choroidal volume and choroidal blood flow are significantly reduced in patients with PDR. In our study, there is a decrease in retinal thickness in diabetic patients and there are no significant differences in the retinal thickness between control subjects and patients with NDR. In agreement with our study, Di et al28 report that there were no significant differences in the retinal thickness between control subjects and patients with NDR, suggesting that retinal vascular alterations precede retinal structural alterations. The decreased retinal thicknesses in diabetic patients reflecting neurodegenerative changes which include reactive gliosis, diminished retinal neuronal function, and neural-cell apoptosis, have been observed to occur before overt microangiopathy in experimental models of diabetic retinopathy and the retina of diabetic donors.29 Progressive thinning of the inner retina over time (assessed by OCT) occurs in murine experimental models.30 Changes in retinal thickness caused by diabetes are not fully understood. Previous studies have found decreased retinal thickness in diabetes with minimal or no DR compared with retinal thickness in non-diabetic individuals.15,31,32 In contrast, other researchers have observed a tendency towards increased retinal thicknesses in individuals with advanced DR.33

There Were Some Limitations to Our Study

The approximately 16 eyes per diabetic group is a relatively small number. Because we measured the choroidal thickness using the manual method, the results might contain slight errors. This was the best clinical method currently available with the current OCT equipment. We tried to ameliorate this by taking two choroidal measurements for the same choroidal point. Choroidal imaging was not performed at a specific time of the day, therefore, we cannot rule out the effect of diurnal variation on the CT as reported previously.34 As is widely known, OCTA has issues regarding various artifacts, and artifacts appear more frequently in eyes with poor vision and retinal diseases.35 In this study, we excluded OCTA images with poor image quality or diabetic macular edema (DME) which might introduce selection bias.36

Conclusion

Our study suggests that OCTA can identify preclinical DR before the manifestation of clinically apparent retinopathy. Our findings also highlight the potential role of OCTA in monitoring and quantifying retinal vascular alterations in diabetes.
  34 in total

1.  Comparison of retinal thicknesses measured using swept-source and spectral-domain optical coherence tomography devices.

Authors:  Colin S Tan; Joel C Chan; Kai Xiong Cheong; Wei Kiong Ngo; SriniVas R Sadda
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-02       Impact factor: 1.300

2.  IMAGE QUALITY AND ARTIFACTS ON OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY: Comparison of Pathologic and Paired Fellow Eyes in 65 Patients With Unilateral Choroidal Melanoma Treated With Plaque Radiotherapy.

Authors:  Emil A T Say; Sandor Ferenczy; George N Magrath; Wasim A Samara; Chloe T L Khoo; Carol L Shields
Journal:  Retina       Date:  2017-09       Impact factor: 4.256

3.  DETECTION OF MICROVASCULAR CHANGES IN EYES OF PATIENTS WITH DIABETES BUT NOT CLINICAL DIABETIC RETINOPATHY USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Authors:  Talisa E de Carlo; Adam T Chin; Marco A Bonini Filho; Mehreen Adhi; Lauren Branchini; David A Salz; Caroline R Baumal; Courtney Crawford; Elias Reichel; Andre J Witkin; Jay S Duker; Nadia K Waheed
Journal:  Retina       Date:  2015-11       Impact factor: 4.256

4.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

5.  IMAGE ARTIFACTS IN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.

Authors:  Richard F Spaide; James G Fujimoto; Nadia K Waheed
Journal:  Retina       Date:  2015-11       Impact factor: 4.256

6.  Choroidal circulation in diabetic patients.

Authors:  G Dimitrova; S Kato; Y Tamaki; H Yamashita; M Nagahara; M Sakurai; S Kitano; H Fukushima
Journal:  Eye (Lond)       Date:  2001-10       Impact factor: 3.775

7.  Foveolar choroidal hemodynamics in proliferative diabetic retinopathy.

Authors:  Lisa S Schocket; Allison J Brucker; Rachel M Niknam; Juan E Grunwald; Joan DuPont; Alexander J Brucker
Journal:  Int Ophthalmol       Date:  2004-03       Impact factor: 2.031

8.  Macular thickness measured by stratus optical coherence tomography in patients with diabetes type 2 and mild nonproliferative retinopathy without clinical evidence of macular edema.

Authors:  Isabel Pires; Ana Rita Santos; Sandrina Nunes; Conceição Lobo
Journal:  Ophthalmologica       Date:  2013-04-24       Impact factor: 3.250

9.  Automated Quantification of Capillary Nonperfusion Using Optical Coherence Tomography Angiography in Diabetic Retinopathy.

Authors:  Thomas S Hwang; Simon S Gao; Liang Liu; Andreas K Lauer; Steven T Bailey; Christina J Flaxel; David J Wilson; David Huang; Yali Jia
Journal:  JAMA Ophthalmol       Date:  2016-04       Impact factor: 7.389

10.  Choroidal thickness in diabetic patients of Indian ethnicity.

Authors:  Aditya Sudhalkar; Jay Kumar Chhablani; Amarnath Venkata; Rajiv Raman; P Srinivasa Rao; Ganesh Babu Jonnadula
Journal:  Indian J Ophthalmol       Date:  2015-12       Impact factor: 1.848

View more
  4 in total

1.  Automated machine learning-based classification of proliferative and non-proliferative diabetic retinopathy using optical coherence tomography angiography vascular density maps.

Authors:  Elias Khalili Pour; Khosro Rezaee; Hossein Azimi; Seyed Mohammad Mirshahvalad; Behzad Jafari; Kaveh Fadakar; Hooshang Faghihi; Ahmad Mirshahi; Fariba Ghassemi; Nazanin Ebrahimiadib; Masoud Mirghorbani; Fatemeh Bazvand; Hamid Riazi-Esfahani; Mohammad Riazi Esfahani
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-09-02       Impact factor: 3.535

2.  Optical Coherence Tomography Angiography in Healthy Adult Subjects: Normative Values, Frequency, and Impact of Artifacts.

Authors:  Nakhleh E Abu-Yaghi; Abdelrahman F Obiedat; Tamara I AlNawaiseh; Ali M Hamad; Basil A Bani Ata; Ahmad A Quzli; Saif Aldeen AlRyalat
Journal:  Biomed Res Int       Date:  2022-03-07       Impact factor: 3.411

3.  Retinal vessel changes in pulmonary arterial hypertension.

Authors:  Mariana DuPont; Savanna Lambert; Antonio Rodriguez-Martin; Okaeri Hernandez; Mark Lagatuz; Taygan Yilmaz; Andrew Foderaro; Grayson L Baird; Patricia Parsons-Wingerter; Tim Lahm; Maria B Grant; Corey E Ventetuolo
Journal:  Pulm Circ       Date:  2022-02-15       Impact factor: 2.886

4.  Quantitative measures of the vascular and neural components of the retina in adult individuals with congenital and untreated growth hormone deficiency.

Authors:  Nelmo V Menezes; Cynthia S Barros-Oliveira; Roberto Salvatori; Vinicius C Gois; Cindi G Marinho; Carla R P Oliveira; Viviane C Campos; Alécia A Oliveira-Santos; Hertz T Santos-Júnior; Elenilde G Santos; Enaldo V Melo; Augusto C N Faro; Neima V Oliveira; Hérika M Gumes-Felix; Gustavo B Melo; Manuel H Aguiar-Oliveira
Journal:  Int J Retina Vitreous       Date:  2022-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.